BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 234 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $176,143 | +0.6% | 24,879 | 0.0% | 0.01% | 0.0% |
| Q2 2023 | $175,148 | -15.6% | 24,879 | 0.0% | 0.01% | -27.3% |
| Q1 2023 | $207,491 | -27.4% | 24,879 | 0.0% | 0.01% | -31.2% |
| Q4 2022 | $285,611 | -8.8% | 24,879 | 0.0% | 0.02% | -27.3% |
| Q3 2022 | $313,000 | -1.3% | 24,879 | -16.9% | 0.02% | -24.1% |
| Q2 2022 | $317,000 | -34.8% | 29,929 | +0.2% | 0.03% | -29.3% |
| Q1 2022 | $486,000 | -8.6% | 29,879 | 0.0% | 0.04% | -10.9% |
| Q4 2021 | $532,000 | +44.2% | 29,879 | 0.0% | 0.05% | +43.8% |
| Q3 2021 | $369,000 | -23.6% | 29,879 | 0.0% | 0.03% | -28.9% |
| Q2 2021 | $483,000 | +15.8% | 29,879 | 0.0% | 0.04% | +9.8% |
| Q1 2021 | $417,000 | +102.4% | 29,879 | +33.2% | 0.04% | +86.4% |
| Q4 2020 | $206,000 | +131.5% | 22,429 | -4.3% | 0.02% | +83.3% |
| Q3 2020 | $89,000 | -17.6% | 23,429 | 0.0% | 0.01% | -14.3% |
| Q2 2020 | $108,000 | +129.8% | 23,429 | 0.0% | 0.01% | +75.0% |
| Q1 2020 | $47,000 | -29.9% | 23,429 | +4.5% | 0.01% | -11.1% |
| Q4 2019 | $67,000 | +4.7% | 22,429 | 0.0% | 0.01% | 0.0% |
| Q3 2019 | $64,000 | -24.7% | 22,429 | 0.0% | 0.01% | -30.8% |
| Q2 2019 | $85,000 | -53.6% | 22,429 | 0.0% | 0.01% | -53.6% |
| Q1 2019 | $183,000 | +1.1% | 22,429 | 0.0% | 0.03% | -12.5% |
| Q4 2018 | $181,000 | +5.8% | 22,429 | 0.0% | 0.03% | +28.0% |
| Q3 2018 | $171,000 | +185.0% | 22,429 | +84.9% | 0.02% | +177.8% |
| Q4 2017 | $60,000 | +39.5% | 12,132 | +222.5% | 0.01% | -70.0% |
| Q3 2015 | $43,000 | -23.2% | 3,762 | 0.0% | 0.03% | -11.8% |
| Q2 2015 | $56,000 | +64.7% | 3,762 | 0.0% | 0.03% | +100.0% |
| Q1 2015 | $34,000 | -65.3% | 3,762 | -62.4% | 0.02% | -67.9% |
| Q3 2014 | $98,000 | -61.6% | 10,000 | -50.0% | 0.05% | -50.0% |
| Q2 2014 | $255,000 | +20.3% | 20,000 | 0.0% | 0.11% | +10.4% |
| Q1 2014 | $212,000 | -25.9% | 20,000 | -46.8% | 0.10% | -5.0% |
| Q4 2013 | $286,000 | +42.3% | 37,600 | +36.2% | 0.10% | -1.9% |
| Q3 2013 | $201,000 | +367.4% | 27,600 | 0.0% | 0.10% | +312.0% |
| Q2 2013 | $43,000 | – | 27,600 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 1,105,673 | $8,237,000 | 6.28% |
| Sarissa Capital Management LP | 8,175,000 | $60,903,000 | 6.22% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,980,870 | $22,207,000 | 2.78% |
| DG Capital Management, LLC | 1,075,732 | $8,014,000 | 1.70% |
| Ghost Tree Capital, LLC | 900,000 | $6,705,000 | 1.49% |
| Parkman Healthcare Partners LLC | 538,370 | $4,011,000 | 1.03% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 5,835,810 | $43,477,000 | 0.86% |
| Formidable Asset Management, LLC | 470,419 | $3,470,000 | 0.80% |
| KNOTT DAVID M | 219,461 | $1,635,000 | 0.74% |
| Altium Capital Management LP | 250,000 | $1,863,000 | 0.70% |